Efficacy and Safety Evaluation of Levetiracetam + Oxcarbazepine in the Treatment of Patients with Epilepsy Secondary to Stroke

Clinical neuroscience research Pub Date : 2024-07-22 DOI:10.26689/cnr.v2i2.7445

Yujing Huang, Zhenggang Wu

{"title":"Efficacy and Safety Evaluation of Levetiracetam + Oxcarbazepine in the Treatment of Patients with Epilepsy Secondary to Stroke","authors":"Yujing Huang, Zhenggang Wu","doi":"10.26689/cnr.v2i2.7445","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the therapeutic efficacy of levetiracetam (LEV) + oxcarbazepine (OXC) for post-stroke secondary epilepsy (PSE) in the elderly. Methods: 92 patients with PSE admitted to the hospital between July 2021 and July 2023 were selected. Random number table grouping was used, with 46 cases in the combination group, selecting LEV + OXC treatment; and 46 cases in the conventional group, selecting OXC treatment, comparing the treatment effect of the two groups. Results: The total effective rate of the combination group was higher than that of the conventional group, and the difference was statistically significant (P < 0.05). Before treatment, in the comparison of the epilepsy-related indexes and blood indexes between the groups, the difference was not statistically significant (P > 0.05). After treatment, the epilepsy-related indicators as well as blood indicators of the combination group were better than those of the conventional group, and the difference was statistically significant (P < 0.05). The adverse reaction rate of the combination group was lower than that of the conventional group, and the difference was statistically significant (P < 0.05). Conclusion: Implementing LEV + OXC therapy for PSE patients can enhance the effectiveness, improve the degree of epilepsy, regulate the blood indexes, and have high therapeutic safety.","PeriodicalId":87465,"journal":{"name":"Clinical neuroscience research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical neuroscience research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/cnr.v2i2.7445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the therapeutic efficacy of levetiracetam (LEV) + oxcarbazepine (OXC) for post-stroke secondary epilepsy (PSE) in the elderly. Methods: 92 patients with PSE admitted to the hospital between July 2021 and July 2023 were selected. Random number table grouping was used, with 46 cases in the combination group, selecting LEV + OXC treatment; and 46 cases in the conventional group, selecting OXC treatment, comparing the treatment effect of the two groups. Results: The total effective rate of the combination group was higher than that of the conventional group, and the difference was statistically significant (P < 0.05). Before treatment, in the comparison of the epilepsy-related indexes and blood indexes between the groups, the difference was not statistically significant (P > 0.05). After treatment, the epilepsy-related indicators as well as blood indicators of the combination group were better than those of the conventional group, and the difference was statistically significant (P < 0.05). The adverse reaction rate of the combination group was lower than that of the conventional group, and the difference was statistically significant (P < 0.05). Conclusion: Implementing LEV + OXC therapy for PSE patients can enhance the effectiveness, improve the degree of epilepsy, regulate the blood indexes, and have high therapeutic safety.

查看原文本刊更多论文

左乙拉西坦+奥卡西平治疗脑卒中继发性癫痫患者的疗效和安全性评估

研究目的评估左乙拉西坦（LEV）+奥卡西平（OXC）治疗老年卒中后继发性癫痫（PSE）的疗效。方法：选取 2021 年 7 月至 2023 年 7 月期间该院收治的 92 例 PSE 患者。采用随机数字表分组，联合组46例，选择LEV+OXC治疗；常规组46例，选择OXC治疗，比较两组治疗效果。结果联合组总有效率高于常规组，差异有统计学意义（P<0.05）。治疗前，组间癫痫相关指标和血液指标比较，差异无统计学意义（P > 0.05）。治疗后，联合组的癫痫相关指标和血液指标均优于常规组，差异有统计学意义（P<0.05）。联合组的不良反应率低于常规组，差异有统计学意义（P < 0.05）。结论对PSE患者实施LEV+OXC治疗可提高疗效，改善癫痫程度，调节血液指标，治疗安全性高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical neuroscience research

自引率

0.00%

发文量